Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma-Reference-Cited by-同舟云学术

Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma

Published:2021-07 Issue:7 Volume:2 Page:693-708
ISSN:2662-1347
Container-title:Nature Cancer
language:en
Short-container-title:Nat Cancer

Author:

Haas Lisa,Elewaut Anais,Gerard Camille L.^ORCID,Umkehrer Christian^ORCID,Leiendecker Lukas^ORCID,Pedersen Malin,Krecioch Izabela,Hoffmann David,Novatchkova Maria,Kuttke Mario^ORCID,Neumann Tobias^ORCID,da Silva Ines Pires,Witthock Harriet,Cuendet Michel A.,Carotta Sebastian,Harrington Kevin J.^ORCID,Zuber Johannes^ORCID,Scolyer Richard A.^ORCID,Long Georgina V.^ORCID,Wilmott James S.^ORCID,Michielin Olivier,Vanharanta Sakari^ORCID,Wiesner Thomas,Obenauf Anna C.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s43018-021-00221-9.pdf

Reference60 articles.

1. Luke, J. et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol. 14, 463–482 (2017).

2. Pavlick, A. C., Fecher, L., Ascierto, P. A. & Sullivan, R. J. Frontline therapy for BRAF-mutated metastatic melanoma: how do you choose, and is there one correct answer? American Society of Clinical Oncology Educational Book 564–571 (American Society of Clinical Oncology, 2019).

3. Robert, C. et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N. Engl. J. Med. 381, 626–636 (2019).

4. Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).

5. Seth, R. et al. Systemic therapy for melanoma: ASCO guideline. J. Clin. Oncol. 38, 3947–3970 (2020).

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolutionary theory of cancer: challenges and potential solutions;Nature Reviews Cancer;2024-09-10

2. Colorectal Cancer with BRAF V600E Mutation: Trends in Immune Checkpoint Inhibitor Treatment;Critical Reviews in Oncology/Hematology;2024-09

3. Extracellular matrix stiffness determines the phenotypic behavior of dedifferentiated melanoma cells through a DDR1/2-dependent YAP mechanotransduction pathway;2024-08-27

4. Molecular Susceptibility and Treatment Challenges in Melanoma;Cells;2024-08-20

5. Determinants of resistance and response to melanoma therapy;Nature Cancer;2024-07-17